<p>HBM HOLDINGS-B (02142.HK) announced its interim results for the six months ending in June, with revenue of USD 101 million, an increase of 327.5% year-on-year. Among this, revenue from molecular licensing fees was USD 93.7 million, up 350%, mainly due to strategic collaborations with global pharmaceutical companies and new licensing of innovative products. It recorded a net profit of USD 71.72 million, a growth of 49.4 times, with earnings per share of 9 cents. No dividend was declared</p>

02142

<p>HBM HOLDINGS-B announced its interim results for the six months ending in June, with revenue of USD 101 million, an increase of 327.5% year-on-year. Among this, revenue from molecule licensing fees was USD 93.7 million, up 350%, mainly due to strategic collaborations with global pharmaceutical companies and newly acquired external licenses for innovative products. It recorded a net profit of USD 71.72 million, a growth of 49.4 times, with earnings per share of 9 cents. No dividend was declared</p>

"Performance" HBM HOLDINGS-B's mid-term net profit of USD 71.72 million increased 49 times, no dividend declared